We are committed to creating the world's most sophisticated, and easy to use, products for genomic and proteomic data analysis, based on our groundbreaking Biomind AI technology. The first products will launch in early 2002, with successively more advanced releases thereafter, exploiting more and more of the Biomind technology's capabilities.
While our underlying technology is complex and subtle, the value proposition we intend to offer our customers is simple. With our products, researchers in the pharmaceutical, biotechnology, and academic fields will be able to
Publish faster.
Bring drugs to market faster.
Obtain crucial patents ahead of the competition
We are in the process of patenting our core bioinformatic technology.
For more information under a non-disclosure agreement, please contact us.